An Update on Drug-induced Liver Injury

被引:191
作者
Devarbhavi, Harshad [1 ]
机构
[1] St Johns Med Coll Hosp, Dept Gastroenterol, Sarjapur Rd, Bangalore, Karnataka, India
关键词
hepatotoxicity; liver injury; DILI; causality; drug-induced;
D O I
10.1016/j.jceh.2012.05.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Idiosyncratic drug-induced liver injury (DILI) is an important cause of morbidity and mortality following drugs taken in therapeutic doses. Hepatotoxicity is a leading cause of attrition in drug development, or withdrawal or restricted use after marketing. No age is exempt although adults and the elderly are at increased risk. DILI spans the entire spectrum ranging from asymptomatic elevation in transaminases to severe disease such as acute hepatitis leading to acute liver failure. The liver specific Roussel Uclaf Causality Assessment Method is the most validated and extensively used for determining the likelihood that an implicated drug caused DILI. Asymptomatic elevation in liver tests must be differentiated from adaptation. Drugs producing DILI have a signature pattern although no single pattern is characteristic. Antimicrobial and central nervous system agents including antiepileptic drugs are the leading causes of DILI worldwide. In the absence of a diagnostic test or a biomarker, the diagnosis rests on the evidence of absence of competing causes such as acute viral hepatitis, autoimmune hepatitis and others. Recent studies show that antituberculosis drugs given for active or latent disease are still a major cause of drug-induced liver injury in India and the West respectively. Presence of jaundice signifies a severe disease and entails a worse outcome. The pathogenesis is unclear and is due to a mix of host, drug metabolite and environmental factors. Research has evolved from incriminating candidate genes to genome wide analysis studies. Immediate cessation of the drug is key to prevent or minimize progressive damage. Treatment is largely supportive. N-acetylcysteine is the antidote for paracetamol toxicity. Carnitine has been tried in valproate injury whereas steroids and ursodeoxycholic acid may be used in DILI associated with hypersensitivity or cholestatic features respectively. This article provides an overview of the epidemiology, the patterns of hepatotoxicity, the pathogenesis and associated risk factors besides its clinical management.
引用
收藏
页码:247 / 259
页数:13
相关论文
共 106 条
[1]
Drug-induced liver injury [J].
Abboud, Gebran ;
Kaplowitz, Neil .
DRUG SAFETY, 2007, 30 (04) :277-294
[2]
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury [J].
Aithal, G. P. ;
Watkins, P. B. ;
Andrade, R. J. ;
Larrey, D. ;
Molokhia, M. ;
Takikawa, H. ;
Hunt, C. M. ;
Wilke, R. A. ;
Avigan, M. ;
Kaplowitz, N. ;
Bjornsson, E. ;
Daly, A. K. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) :806-815
[3]
Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? [J].
Aithal, GP ;
Haugk, B ;
Das, S ;
Card, T ;
Burt, AD ;
Record, CO .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (04) :391-399
[4]
Dangerous liaisons: Drug, host and the environment [J].
Aithal, Guruprasad P. .
JOURNAL OF HEPATOLOGY, 2007, 46 (06) :995-998
[5]
Rechallenge in drug-induced liver injury: the attractive hazard [J].
Andrade, Raul J. ;
Robles, Mercedes ;
Lucena, Maria Isabel .
EXPERT OPINION ON DRUG SAFETY, 2009, 8 (06) :709-714
[6]
Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Pelaez, G ;
Pachkoria, K ;
García-Ruiz, E ;
García-Munoz, B ;
González-Grande, R ;
Pizarro, A ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Romero-Gomez, M ;
Navarro, JM ;
Planas, R ;
Costa, J ;
Borras, A ;
Soler, A ;
Salmerón, J ;
Martin-Vivaldi, R .
GASTROENTEROLOGY, 2005, 129 (02) :512-521
[7]
HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease [J].
Andrade, RJ ;
Lucena, MI ;
Alonso, A ;
García-Cortes, M ;
García-Ruiz, E ;
Benitez, R ;
Fernández, MC ;
Pelaez, G ;
Romero, M ;
Corpas, R ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Nogueras, F ;
Martín-Vivaldi, R ;
Navarro, JM ;
Salmerón, J ;
de la Cuesta, FS ;
Hidalgo, R .
HEPATOLOGY, 2004, 39 (06) :1603-1612
[8]
[Anonymous], 1972, World Health Organ Tech Rep Ser, V498, P1
[9]
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity [J].
Baniasadi, Shadi ;
Eftekhari, Parivash ;
Tabarsi, Payam ;
Fahimi, Fanak ;
Raoufy, Mohammad Reza ;
Masjedi, Mohammad Reza ;
Velayati, Ali Akbar .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (10) :1235-1238
[10]
BENICHOU C, 1990, J HEPATOL, V11, P272